Clinical data | |
---|---|
Trade names | Bilessglu |
Other names | Carfloglitazar |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C36H29FN2O4 |
Molar mass | 572.636 g·mol−1 |
3D model (JSmol) | |
| |
|
Chiglitazar (trade name Bilessglu) is a drug for the treatment of type 2 diabetes.[1] It is a peroxisome proliferator-activated receptor (PPAR) agonist.
In China, chiglitazar is approved for glycemic control in adult patients with type 2 diabetes when used in combination with diet and exercise.[2]
References
- ↑ Ji, Linong; et al. (2021). "Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)". Science Bulletin. 66 (15): 1571–1580. Bibcode:2021SciBu..66.1571J. doi:10.1016/j.scib.2021.03.019. PMID 36654286. S2CID 233650336.
- ↑ Deeks, Emma D. (2022). "Chiglitazar: First Approval". Drugs. 82 (1): 87–92. doi:10.1007/s40265-021-01648-1. PMID 34846697. S2CID 244716275.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.